Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST-IC: COVID-19 Vaccine Schedules in Immunocompromised Populations
NCT05556720Phase 3Active, not recruiting
- Sponsor
- Monash University
- Start
- Dec 2022
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Pfizer Bivalent COVID-19 Vaccine, elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19), sponsored by Monash University. Started Dec 2022; status: active, not recruiting.
02
Drugs
Pfizer Bivalent COVID-19 Vaccineelasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05556720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556720.